Compare MUX & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUX | NRIX |
|---|---|---|
| Founded | 1979 | 2009 |
| Country | Canada | United States |
| Employees | 1432 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 2020 |
| Metric | MUX | NRIX |
|---|---|---|
| Price | $24.11 | $16.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $26.63 | ★ $30.50 |
| AVG Volume (30 Days) | 913.5K | ★ 1.2M |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $37.86 | N/A |
| Revenue Next Year | $31.10 | $48.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $7.15 | $8.20 |
| 52 Week High | $29.70 | $22.50 |
| Indicator | MUX | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 52.99 |
| Support Level | $22.96 | $15.62 |
| Resistance Level | $24.88 | $16.71 |
| Average True Range (ATR) | 1.18 | 0.88 |
| MACD | 0.50 | 0.14 |
| Stochastic Oscillator | 62.88 | 52.24 |
McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.